Pharvaris' innovative approach to treating hereditary angioedema (HAE) with deucrictibant. Read here for an investment ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and released financial results for the fiscal year ended April 30, 2025.

The attack data in RAPIDe-3 have continued to accrue following the achievement of target enrollment in the study; we now estimate that our RAPIDe-3 topline data announcement will be in the fourth ...

By targeting a previously unexploited metabolic pathway essential for bacterial survival, the drug candidate may offer the potential to develop safer, shorter and more effective treatment regimens ...

Your healthcare provider may also recommend a TB test — either a blood test or a skin test. For the skin test, you will need ...

The company announced that the US FDA approved Yeztugo ® (lenacapavir), Gilead Sciences, Inc. (NASDAQ:GILD)’s injectable HIV-1 capsid inhibitor, as pre-exposure prophylaxis (PrEP) in order to ...

Study findings suggest that information needs of many women undergoing prophylactic mastectomy have not been sufficiently addressed.

Background The diagnosis of childhood tuberculosis remains a challenge worldwide. The Xpert MTB/RIF test, a rapid mycobacteria tuberculosis diagnostic tool, was recommended for use in children ...

View the latest INDUS Holding AG (INH) stock price, news, historical charts, analyst ratings and financial information from WSJ.

They also may have a genetic condition that increases their likelihood. Medicare may or may not cover a prophylactic mastectomy, and coverage is reviewed on an individual basis.